This clinical trial is for adult participants who have advanced blood cancer that has been previously treated and is now unresponsive.
   
The purpose of this study is to learn more about the safety and effectiveness of using an investigational drug, NC525, in the treatment of blood cancer. An “Investigational” drug means it has not been approved for marketing by any health authority including the U.S. Food and Drug Administration (FDA).
   
Participants will be asked to complete the following research procedures: take the study drug, NC525; provide information related to previous medical and social history; undergo complete physical exams including vital signs; and provide blood and bone marrow samples.
   
The study agent NC525 will be administered via infusion into a participant's vein. Participants will receive the infusion weekly during the first 2 cycles and every two weeks for each cycle after that. Each cycle will last 28 days.
   
Participation will last up to approximately two years or until a participant’s disease progresses or they experience side effects that require treatment to be stopped. If a participant decides to discontinue study treatment, they will be asked to continue to participate in safety follow-up procedures and to allow the research team to continue to utilize their medical information.